Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008

University of California, Berkeley, Berkeley, California, United States
AIDS (Impact Factor: 5.55). 08/2007; 21 Suppl 4(Suppl 4):S97-103. DOI: 10.1097/01.aids.0000279712.32051.29
Source: PubMed


Middle and low-income countries have scaled up HIV treatment in the past 5 years. To maintain this effort, information regarding the amounts and types of drugs is needed. Shortages or overstock of active pharmaceutical ingredients make the scale-up efforts more difficult and costly. To inform global planning and implementation, we estimate the volume of current and future demand for active pharmaceutical ingredients for first and second-line antiretroviral drugs.
Using regression analysis and documented assumptions, we estimated the number of individuals receiving antiretroviral drugs to 2008. The volume of active pharmaceutical ingredients was calculated using two methods: a normative approach modelling implementation of country-specific guidelines, and an empirical model projecting current trends in drug use estimated by a survey of country HIV programmes.
The number of patients treated was estimated to reach 3.38 million by the end of 2008, of which 94.6% would be on first-line and 5.4% on second-line treatment. The largest estimated absolute demand volumes for 2008 were for nevirapine, lamivudine, and zidovudine using either approach; the largest proportional increases in 2007-2008, were observed for emtricitabine, tenofovir, indinavir, and nelfinavir. The gap between normative and empirical estimates was greatest (most positive) for tenofovir, zidovudine, didanosine, and smallest (most negative) for saquinavir and nelfinavir.
A comparison of the results from the normative and empirical demand quantities suggests that more tenofovir, zidovudine and didanosine would be required if national treatment guidelines were fully implemented, whereas the countries seem to be using more saquinavir and nelfinavir than would be required by their current guidelines.

8 Reads
  • Source
    • "The new forecasts presented here update previous estimates [2] [3] [4] by adding updated information on the number of people receiving antiretroviral therapy and data from the annual WHO AIDS Medicines and Diagnostics Service (AMDS) survey on the use of antiretrovirals [5] [6] [7]. Two major elements taken into account for developing updated forecasts were the financial crisis and the progressive implementation of the new WHO antiretroviral therapy (ART) recommendations published in 2010 [8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. The rapid scale-up of antiretroviral therapy in resource-limited settings has greatly increased demand for antiretroviral medicines and raised the importance of good forward planning, especially in the context of the new 2010 WHO treatment guidelines. Methods. Forecasting of the number of people receiving antiretroviral therapy from 2010 to 2012 was produced using three approaches: linear projection, country-set targets, and a restricted scenario. Two additional scenarios were then used to project the demand for various antiretroviral medicines under a fast and slower phase-out of stavudine. Results. We projected that between 7.1 million and 8.4 million people would be receiving ART by the end of 2012. Of these, 6.6% will be on second-line therapy. High variation in forecast includes reductions in the demand for d4T and d4T increases in the demand for tenofovir, emtricitabine followed by efavirenz, ritonavir, zidovudine and lopinavir; lamivudine, atazanavir, and nevirapine. Conclusion. Despite the global economic crisis and in response to the revised treatment guidelines, our model forecasts an increasing and shifting demand for antiretrovirals in resource-limited settings not only to provide treatment to new patients, but also to those switching to less toxic regimens.
    AIDS research and treatment 03/2011; 2011:749041. DOI:10.1155/2011/749041
  • Source
    • "It is particularly important to assess adherence during HAART programs, mainly owing to the limited availability of alternative regimens [13]. Indeed, poor adherence can lead to the emergence of drug resistance [14] [15] [16], notably to first-line nonnucleoside reverse transcriptase inhibitor (NNRTI-)based regimens recommended by WHO. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Adherence to antiviral therapy is important for HIV-infected people living in low- and middle-income countries, because of poor access to alternative regimens. Methods. We conducted a cross-sectional survey of adherence in Cambodian patients enrolled in the ESTHER program and treated with WHO first-line regimen for at least 6 months. The survey was based on a self-report questionnaire, drug assay, MCV measurement, visual analog scale, and viral load HIV RNA. Results. Two hundred fifty-nine patients treated for a median of 16 months participated in the survey. At inclusion in the program, 158 patients (61%) were ARV-naïve. The virological success rate was 71% overall and 81% in previously ARV-naive patients. Considered individually, the measures suggested perfect adherence in 71% to 93% of patients. In multivariate analysis adjusted for sex and therapeutic status before HAART initiation, only the biological markers were associated with virological efficacy. Self-funded treatment before entry to the program was highly predictive of virological failure. Conclusion. Adherence was excellent in these Cambodian patients. Biological markers were predictive of virological efficacy. MCV might thus serve as a simple alternative for assessing adherence and predicting virological efficacy among patients receiving AZT- or d4T-based regimens.
    AIDS research and treatment 01/2010; 2010:142076. DOI:10.1155/2010/142076
  • AIDS 08/2007; 21 Suppl 4:S1-4. DOI:10.1097/01.aids.0000279700.86309.f6 · 5.55 Impact Factor
Show more